When people talk about gut health, the conversation typically revolves around digestion, bloating, or stool microbiome kits. But some of the most informative signals about what is happening inside your gastrointestinal tract do not require a stool sample at all — they circulate in your blood, and they originate from a single amino acid: tryptophan.
Kynurenine (KYN), indole-3-propionic acid (IPA), and the enzymatic activity of indoleamine 2,3-dioxygenase (IDO) represent three measurable facets of how your body and your gut microbiome collectively metabolise tryptophan. Together, they offer a biochemical window into gut-immune crosstalk, microbial diversity, and intestinal barrier integrity — from a standard blood draw. This article explains how these markers are generated, what they reflect, and why their plasma levels carry meaningful information about gut health at the systemic level.
1. Tryptophan: The Shared Precursor
Tryptophan is an essential amino acid obtained exclusively from dietary protein. Once absorbed, it does not simply contribute to protein synthesis — the majority of ingested tryptophan is actively catabolised through competing metabolic routes, each producing distinct classes of bioactive compounds.
Three main pathways partition tryptophan after absorption. First, a small fraction — roughly 1 to 3% — is directed toward serotonin synthesis via tryptophan hydroxylase, primarily in enterochromaffin cells of the gut mucosa. Second, and by far the most quantitatively dominant route, the kynurenine pathway (KP) accounts for the metabolism of approximately 90% of systemic tryptophan, converting it through a cascade of enzymatic steps into kynurenine and its downstream metabolites, including kynurenic acid, quinolinic acid, and ultimately nicotinamide adenine dinucleotide (NAD⁺). Third, gut bacteria intercept a portion of luminal tryptophan and metabolise it through an entirely separate indole pathway, generating indole derivatives including indole-3-propionic acid (IPA), indole-3-acetic acid, and indole-3-lactic acid.
The biological fate of tryptophan is therefore not determined solely by host biochemistry — it is shaped in real time by the composition and metabolic activity of the gut microbiome. This makes tryptophan metabolite profiles in blood uniquely informative: they reflect both immune status and microbial ecology simultaneously.
2. The Kynurenine Pathway and IDO Activity
The kynurenine pathway is initiated by one of two rate-limiting enzymes: tryptophan 2,3-dioxygenase (TDO), which operates primarily in the liver and responds to tryptophan availability and glucocorticoid signals, and indoleamine 2,3-dioxygenase (IDO) — specifically its isoform IDO1 — which is expressed broadly in immune cells, intestinal epithelium, macrophages, and dendritic cells.
IDO1 is the immunologically responsive enzyme. Its activity is powerfully induced by pro-inflammatory cytokines, particularly interferon-gamma (IFN-γ), but also interleukin-1 (IL-1), interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-α). In the context of infection, chronic inflammation, or gut dysbiosis, IDO1 upregulation accelerates the conversion of tryptophan into N-formylkynurenine, which is immediately hydrolysed into kynurenine (KYN) — the first stable product of the pathway.
Because IDO1 cannot be directly measured in blood under routine clinical conditions, its activity is estimated indirectly using the KYN:TRP ratio — the ratio of plasma kynurenine to plasma tryptophan. When IDO activity increases, tryptophan is more rapidly consumed and kynurenine rises; the ratio therefore serves as a proxy for immune-driven tryptophan catabolism. Research has validated the KYN:TRP ratio as a surrogate marker of IDO1 activation in a range of contexts, from inflammatory bowel disease to chronic metabolic conditions.
It is worth emphasising that IDO activation serves immunological purposes: it helps regulate T-cell responses, promotes immune tolerance, and contributes to local immunosuppression. The enzyme plays a role in preventing excessive immune activation. However, chronically elevated IDO activity — sustained by ongoing systemic inflammation or gut immune dysregulation — comes at a cost. It depletes circulating tryptophan, thereby reducing the substrate available for serotonin synthesis, and it generates downstream metabolites such as quinolinic acid, which has documented neurotoxic properties via NMDA receptor activation. High IDO activity in the context of gut disease has been linked to depressive symptomatology, in part through these tryptophan-depleting and neuroactive mechanisms.
3. Kynurenine in Blood: Reading the Downstream Signal
Circulating kynurenine provides a measurable downstream indicator of IDO pathway flux. Elevated plasma KYN, particularly when expressed relative to tryptophan, suggests that the kynurenine pathway is operating at higher-than-baseline intensity — typically a signal of immune activation upstream.
In gastrointestinal contexts specifically, IDO1 overexpression has been documented in the colonic mucosa of patients with inflammatory bowel disease. Increased mucosal IDO activity correlates with endoscopic evidence of inflammation in ulcerative colitis, and systemic KYN:TRP ratios tend to be higher in active versus remission states. Activation of toll-like receptors (TLRs) by microbial components — including lipopolysaccharides (LPS) from gram-negative bacteria — is among the mechanisms by which gut dysbiosis can trigger IDO upregulation and elevate circulating kynurenine.
Beyond inflammatory bowel conditions, elevated KYN:TRP has been associated with broader cardiometabolic risk contexts, including insulin resistance and non-alcoholic fatty liver disease, conditions where chronic low-grade gut-derived inflammation is increasingly recognised as a contributing mechanism. A shift in plasma kynurenine thus reflects not just gut mucosal immune activity but its systemic metabolic consequences.
KYN itself also has immunomodulatory effects: it acts on the aryl hydrocarbon receptor (AhR), influencing T-regulatory cell differentiation and Th17 responses. The net immunological outcome depends on the balance of downstream metabolites — kynurenic acid (neuroprotective and immunosuppressive) versus quinolinic acid and 3-hydroxykynurenine (pro-oxidant and neurotoxic). The KYN:KYNA and KYN:QA ratios therefore carry additional interpretive nuance for those with access to broader tryptophan metabolite profiling.
4. Indole-3-Propionic Acid (IPA): The Microbiome's Protective Messenger
While the kynurenine pathway is a host-driven route initiated primarily by immune signals, IPA production operates on an entirely different logic: it is generated exclusively by gut bacteria through anaerobic tryptophan deamination, and is absent — or nearly so — when the microbiome is disrupted.
IPA is produced by a specific enzymatic system present mainly in gram-positive anaerobes, including Clostridium sporogenes, Anaerobutyricum hallii, and members of the Lactobacillus and Akkermansia genera. The synthesis of IPA is critically dependent on microbial community structure: if the relevant enzyme genes are absent from the microbiome, IPA production collapses. This makes plasma IPA a functional readout of anaerobic microbial metabolic capacity — and, by extension, of microbiome diversity and ecological stability.
After synthesis in the colon, IPA is absorbed across the intestinal epithelium and enters systemic circulation, where it can be measured in plasma. Its circulating levels reflect the interplay of dietary tryptophan intake, microbial community composition, and host intestinal absorption capacity — making it a genuinely integrative signal of gut ecosystem status.
The biological functions of IPA are extensive and broadly protective. Research suggests IPA stimulates the expression of tight junction proteins — including ZO-1 and occludin — at the intestinal epithelium, supporting barrier integrity and reducing paracellular permeability. A more robust intestinal barrier reduces translocation of microbial endotoxins (LPS) into the portal circulation, attenuating downstream hepatic inflammation and systemic immune activation. In preclinical models of non-alcoholic steatohepatitis, IPA administration reduced plasma endotoxin levels and inhibited NF-κB-dependent inflammatory signalling in macrophages, with measurable reduction in pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6.
Beyond its barrier effects, IPA has been studied for its antioxidant properties, its capacity to modulate AhR and pregnane X receptor (PXR) signalling, and its neuroprotective potential via blood-brain barrier support. In clinical data from the TwinsUK cohort — over one thousand middle-aged women — serum IPA was positively and significantly correlated with gut microbiome alpha diversity, reinforcing its status as a proxy for microbial ecosystem health rather than just a single-species output.
Clinically, lower plasma IPA has been observed in patients with type 2 diabetes, obesity, and NAFLD compared to metabolically healthy controls, and has been proposed as a candidate biomarker for early metabolic disease risk stratification. Studies have also reported that IPA levels are suppressed by antibiotic use and recover in parallel with microbiome reconstitution — a direct demonstration of its microbial dependence.
5. KYN and IPA Together: A Dual Window into Gut-Immune Status
Considered in isolation, neither KYN/IDO activity nor IPA provides a complete picture. Their interpretive power increases substantially when read in tandem, because they index different — and in some ways opposing — aspects of the gut-immune interface.
Elevated KYN:TRP with low IPA represents a pattern that may suggest both active immune-driven tryptophan catabolism (IDO activation) and impaired microbial protective capacity. This combination has been documented in inflammatory gut conditions, metabolic syndrome, and states of dysbiosis with barrier compromise. The two biomarkers pull in different directions: IDO activation depletes tryptophan and generates neuroactive downstream metabolites, while IPA production by a healthy microbiome protects the barrier and suppresses inflammatory cytokine cascades. When IDO is upregulated and IPA is low, both signals converge on a picture of gut-immune dysregulation.
Conversely, low KYN:TRP combined with high IPA would be more consistent with a microbially diverse gut, low-grade systemic inflammation, and intact barrier function. This is the metabolic phenotype broadly associated with metabolic resilience in the current literature.
It is important to note that tryptophan metabolite profiles should not be interpreted in isolation from other inflammatory and metabolic markers. The KYN:TRP ratio is influenced by factors beyond gut health — including systemic infection, autoimmune activation, psychological stress (via glucocorticoid effects on TDO), and cancer immunology. Context — clinical, dietary, and lifestyle — is essential for accurate interpretation.
6. Biomarker Mapping
The following table maps the core concepts in this article to their measurable biomarker equivalents and preferred analytical methods:
- IDO1 enzymatic activity (indirect) → KYN:TRP ratio (plasma kynurenine ÷ plasma tryptophan) → measured by LC-MS/MS; both analytes quantified simultaneously from a single plasma sample
- Kynurenine pathway flux → Plasma kynurenine (KYN) → LC-MS/MS; absolute concentration and ratio to tryptophan
- Tryptophan bioavailability → Plasma free tryptophan (TRP) → LC-MS/MS amino acid profiling
- Microbiome-derived gut barrier signal → Plasma indole-3-propionic acid (IPA) → LC-MS/MS; indole metabolite profiling panel
- Systemic inflammatory context → High-sensitivity CRP (hsCRP), IL-6 → immunoassay; essential for contextualising KYN:TRP elevations
- Gut barrier integrity (indirect) → Plasma lipopolysaccharide-binding protein (LBP) or zonulin → immunoassay; complementary markers of barrier compromise
- NAD⁺ downstream context → Whole-blood NAD⁺ → enzymatic cycling assay or LC-MS/MS; reflects kynurenine pathway contribution to NAD⁺ synthesis
Primary biomarkers: plasma KYN, plasma TRP (and derived KYN:TRP ratio), plasma IPA.
Secondary contextual biomarkers: hsCRP, IL-6, whole-blood NAD⁺, LBP or zonulin, broader one-carbon metabolism markers where relevant.
Preferred analytical platform: liquid chromatography-tandem mass spectrometry (LC-MS/MS) for all tryptophan metabolites and IPA, due to the structural similarity of indole compounds and the need for precise quantification at low nanomolar concentrations.
7. How Biostarks Can Help
Tryptophan metabolite profiling — including kynurenine, tryptophan, and indole derivatives such as IPA — sits at the intersection of mass spectrometry capability and clinical interpretation. Standard immunoassay-based panels do not capture these analytes; they require the specificity and sensitivity of LC-MS/MS to distinguish structurally similar metabolites at physiologically relevant concentrations.
Biostarks' analytical platform is built on high-resolution mass spectrometry, making it well-positioned to support tryptophan pathway profiling as part of a broader metabolic health assessment. For individuals interested in gut-immune health, inflammatory context, or microbiome functional status, combining KYN:TRP ratio and plasma IPA with markers from the Metabolic Health panel — including inflammatory and hepatic markers — can provide a more integrated view of systemic gut-derived immune load. The Nutrition panel, which captures amino acid status, further supports tryptophan bioavailability interpretation in the context of dietary adequacy.
As with all biomarkers, these measurements are most meaningful when tracked longitudinally and interpreted alongside clinical context — not as isolated data points, but as part of a coherent metabolic narrative.
References
- Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health — Science — Cervenka et al. — (2017) — Source
- Microorganisms, Tryptophan Metabolism, and Kynurenine Pathway: A Complex Interconnected Loop Influencing Human Health Status — International Journal of Tryptophan Research — Dehhaghi et al. — (2019) — Source
- Tryptophan Metabolites Along the Microbiota-Gut-Brain Axis: An Interkingdom Communication System Influencing the Gut in Health and Disease — International Journal of Molecular Sciences — Bosi et al. — (2020) — Source
- Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain — Frontiers in Cellular and Infection Microbiology — PMC — (2020) — Source
- The Kynurenine Pathway in Gut Permeability and Inflammation — Inflammation — Springer Nature — (2024) — Source
- Kynurenine pathway metabolism and the microbiota-gut-brain axis — Neuropharmacology — Kennedy et al. — (2017) — Source
- Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats — Experimental & Molecular Medicine — Nature — (2019) — Source
- Extensive Summary of the Important Roles of Indole Propionic Acid, a Gut Microbial Metabolite in Host Health and Disease — Nutrients — (2023) — Source
- The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders — Frontiers in Endocrinology — (2022) — Source
- Indole Propionic Acid Regulates Gut Immunity: Mechanisms of Metabolite-Driven Immunomodulation and Barrier Integrity — PMC — (2025) — Source
- The Kynurenine Pathway as a Novel Link between Allergy and the Gut Microbiome — Frontiers in Immunology — (2017) — Source
- Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease — Journal of Neuroinflammation — (2021) — Source
